Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis - PubMed
4 hours ago
- #network meta-analysis
- #antidiabetic drugs efficacy
- #chronic kidney disease
- Novel antidiabetic drugs, including SGLT-2is, GLP-1RAs, and DPP-4is, are analyzed for efficacy and safety in patients with type 2 diabetes and chronic kidney disease.
- A network meta-analysis of 30 studies involving 39,844 participants used Bayesian methods to rank interventions based on SUCRA values.
- Sotagliflozin ranked highest in reducing major adverse cardiovascular events, while empagliflozin ranked first for improving composite renal outcomes and reducing all-cause mortality.
- Canagliflozin was best for reducing adverse events, and a combination of dapagliflozin + exenatide ranked first in reducing hypoglycemic events.
- Semaglutide ranked first in reducing cardiovascular mortality, indicating that optimal interventions vary by specific outcome.